Literature DB >> 22654452

Detection of eukaryotic translation initiation factor 4E and its clinical significance in hepatocellular carcinoma.

Xiao-Lin Wang1, Hong-Pei Cai, Jun-Hui Ge, Xiao-Feng Su.   

Abstract

AIM: To study the expression of eukaryotic translation initiation factor 4E (eIF4E), which is closely correlated with malignant tumors, and its relationship to prognosis in hepatocellular carcinoma.
METHODS: Western blotting was performed to quantify the elF4E protein expression in the normal human liver cell line L02 and the hepatoma cell lines Hep3B, HepG2, and Huh7. Forty-six hepatocellular carcinoma samples with complete clinical data were obtained from Changzheng Hospital during the period of December 2008 to July 2009. The expression of eIF4E in the tumor samples and their adjacent tissues were detected by immunohistochemistry. The relationship between the test results and hepatocellular carcinoma (HCC) prognosis was statistically analysed by using a COX proportional hazard model.
RESULTS: Western blotting analysis showed that there were distinct eIF4E protein bands in all three of the hepatoma cell lines. In particular, the HepG2 cell line had the highest level of eIF4E protein expression. The L02 cell group had a low eIF4E expression. Immunohistochemical assay showed that there were 32 cases in which the tumour tissue expression was higher than their adjacent tissues, accounting for 69.57%. There were also 14 cases in which the tumour tissue expression was lower or no significant difference was found, accounting for 30.43%. COX proportional hazards model analysis showed that HCC prognosis was related to the depth of invasion, the overexpression of eIF4E and p53, possibly as independent HCC prognostic predictors.
CONCLUSION: In summary, eIF4E expression is associated with liver cancer, and patients with high eIF4E expression levels have a higher risk of recurrence.

Entities:  

Keywords:  Eukaryotic translation initiation factor 4E; Hepatocellular carcinoma; Immunohistochemistry; Prognosis; Western blotting

Mesh:

Substances:

Year:  2012        PMID: 22654452      PMCID: PMC3360453          DOI: 10.3748/wjg.v18.i20.2540

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

1.  A prospective trial on initiation factor 4E (eIF4E) overexpression and cancer recurrence in node-positive breast cancer.

Authors:  Derek R McClusky; Quyen Chu; Herbert Yu; Arrigo Debenedetti; Lester W Johnson; Carol Meschonat; Richard Turnage; John C McDonald; Fleurette Abreo; Benjamin D L Li
Journal:  Ann Surg       Date:  2005-10       Impact factor: 12.969

2.  Sumoylation of eIF4E activates mRNA translation.

Authors:  Xiang Xu; Jaya Vatsyayan; Chenxi Gao; Christopher J Bakkenist; Jing Hu
Journal:  EMBO Rep       Date:  2010-03-12       Impact factor: 8.807

3.  Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer.

Authors:  Andrew C Hsieh; Davide Ruggero
Journal:  Clin Cancer Res       Date:  2010-08-11       Impact factor: 12.531

4.  Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma.

Authors:  Chel Hun Choi; Ji-Soo Lee; Seong Rim Kim; Yoo-Young Lee; Chul-Jung Kim; Jeong-Won Lee; Tae-Joong Kim; Je-Ho Lee; Byoung-Gie Kim; Duk-Soo Bae
Journal:  J Cancer Res Clin Oncol       Date:  2010-05-13       Impact factor: 4.553

5.  Detection of the proto-oncogene eIF4E in surgical margins may predict recurrence in head and neck cancer.

Authors:  C A Nathan; L Liu; B D Li; F W Abreo; I Nandy; A De Benedetti
Journal:  Oncogene       Date:  1997-07-31       Impact factor: 9.867

6.  Inhibition of eIF4E phosphorylation reduces cell growth and proliferation in primary central nervous system lymphoma cells.

Authors:  Daisuke Muta; Keishi Makino; Hideo Nakamura; Shigetoshi Yano; Mareina Kudo; Jun-Ichi Kuratsu
Journal:  J Neurooncol       Date:  2010-05-25       Impact factor: 4.130

7.  Eukaryotic initiation factor 4E overexpression in triple-negative breast cancer predicts a worse outcome.

Authors:  Anthony Flowers; Quyen D Chu; Lori Panu; Carol Meschonat; Gloria Caldito; Mary Lowery-Nordberg; Benjamin D L Li
Journal:  Surgery       Date:  2009-08       Impact factor: 3.982

8.  Overexpression of eukaryotic initiation factor 4E (eIF4E) and its clinical significance in lung adenocarcinoma.

Authors:  Rui Wang; Jian Geng; Jing-hua Wang; Xiao-yuan Chu; Huai-cheng Geng; Long-bang Chen
Journal:  Lung Cancer       Date:  2009-03-03       Impact factor: 5.705

9.  Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissues.

Authors:  Songqing Fan; Suresh S Ramalingam; John Kauh; Zhiheng Xu; Fadlo R Khuri; Shi-Yong Sun
Journal:  Cancer Biol Ther       Date:  2009-08-08       Impact factor: 4.742

10.  Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis.

Authors:  Aurelia Noske; Juliane Lena Lindenberg; Silvia Darb-Esfahani; Wilko Weichert; Ann-Christin Buckendahl; Annika Röske; Jalid Sehouli; Manfred Dietel; Carsten Denkert
Journal:  Oncol Rep       Date:  2008-12       Impact factor: 3.906

View more
  17 in total

1.  O-GlcNAcylation of core components of the translation initiation machinery regulates protein synthesis.

Authors:  Xuexia Li; Qiang Zhu; Xiaoliu Shi; Yaxian Cheng; Xueliu Li; Huan Xu; Xiaotao Duan; Linda C Hsieh-Wilson; Jennifer Chu; Jerry Pelletier; Maowei Ni; Zhiguo Zheng; Sihui Li; Wen Yi
Journal:  Proc Natl Acad Sci U S A       Date:  2019-04-02       Impact factor: 11.205

2.  4EBP1/eIF4E and p70S6K/RPS6 axes play critical and distinct roles in hepatocarcinogenesis driven by AKT and N-Ras proto-oncogenes in mice.

Authors:  Chunmei Wang; Antonio Cigliano; Lijie Jiang; Xiaolei Li; Biao Fan; Maria G Pilo; Yan Liu; Bing Gui; Marcella Sini; Jeffrey W Smith; Frank Dombrowski; Diego F Calvisi; Matthias Evert; Xin Chen
Journal:  Hepatology       Date:  2014-11-25       Impact factor: 17.425

3.  The translation initiation factor eIF3i up-regulates vascular endothelial growth factor A, accelerates cell proliferation, and promotes angiogenesis in embryonic development and tumorigenesis.

Authors:  Yike Yuan; Yaguang Zhang; Shaohua Yao; Huashan Shi; Xi Huang; Yuhao Li; Yuquan Wei; Shuo Lin
Journal:  J Biol Chem       Date:  2014-08-21       Impact factor: 5.157

4.  Prognostic significance of eukaryotic initiation factor 4E in hepatocellular carcinoma.

Authors:  Xue-Mei Jiang; Xiang-Nan Yu; Ren-Zheng Huang; Hai-Rong Zhu; Xiao-Peng Chen; Ju Xiong; Zheng-Yi Chen; Xiao-Xi Huang; Xi-Zhong Shen; Ji-Min Zhu
Journal:  J Cancer Res Clin Oncol       Date:  2016-09-06       Impact factor: 4.553

5.  EIF4E over-expresses and enhances cell proliferation and cell cycle progression in nasopharyngeal carcinoma.

Authors:  Mengyan Wu; Yingxia Liu; Xiaoqing Di; Haixian Kang; Hua Zeng; Yi Zhao; Kangrong Cai; Tianyun Pang; Sen Wang; Yunhong Yao; Xinrong Hu
Journal:  Med Oncol       Date:  2013-01-01       Impact factor: 3.064

6.  Phospho-4e-BP1 and eIF4E overexpression synergistically drives disease progression in clinically confined clear cell renal cell carcinoma.

Authors:  Lee Campbell; Bharat Jasani; David Fr Griffiths; Mark Gumbleton
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

Review 7.  Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.

Authors:  Shakur Mohibi; Xinbin Chen; Jin Zhang
Journal:  Pharmacol Ther       Date:  2019-07-11       Impact factor: 12.310

8.  Implications of the Use of Eukaryotic Translation Initiation Factor 5A (eIF5A) for Prognosis and Treatment of Hepatocellular Carcinoma.

Authors:  Felix H Shek; Sarwat Fatima; Nikki P Lee
Journal:  Int J Hepatol       Date:  2012-09-18

9.  Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.

Authors:  Takayuki Kogure; A Douglas Kinghorn; Irene Yan; Brad Bolon; David M Lucas; Michael R Grever; Tushar Patel
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

Review 10.  Role of RONS and eIFs in Cancer Progression.

Authors:  Yasmeen Ahmed Salaheldin; Salma Sayed Mohamed Mahmoud; Ebenezeri Erasto Ngowi; Vivian Aku Gbordzor; Tao Li; Dong-Dong Wu; Xin-Ying Ji
Journal:  Oxid Med Cell Longev       Date:  2021-07-05       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.